Acadia Pharma (ACAD): Offering Bridges Commercial Activities To 2019 - Piper Jaffray
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after ACADIA, yesterday, completed an offering of ~6M shares, raising $188M in net proceeds and pro-forma cash to ~$545M. The analyst believes this offering means the company’s clinical and commercial activities are well-funded into 1H19.
During this time, he expected ACADIA to make significant progress on the NUPLAZID commercial launch in the US and submit a marketing application in the EU. He believes the company can produce positive, potentially pivotal-stage data in AD agitation and advance NUPLAZID in a third possible indication such as schizophrenia or LBD.
Overall, he views the strengthened balance sheet as a positive in terms of supporting the marketing efforts needed for a successful PDP launch and funding clinical development to generate upside additional large-market neuro-psych indications. In advance of increased visibility on early traction in PDP, Phase II ADP data, and a Phase II/III ADA trial start by YE16,
No change to the price target of $44.00
Shares of Acadia Pharmaceuticals closed at $32.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharma (ACAD): Nuplazid KOL Follow-Up Call - Needham
- Goldman Sachs Starts Hertz Global (HTZ) at 'Sell' and Avis Budget (CAR) at 'Neutral'
- Jefferies Raises Price Target on FMC Technologies (FTI) After Adjusting Estimates
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!